[Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: a randomized controlled trial]
- PMID: 22704410
- DOI: 10.3736/jcim20120605
[Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: a randomized controlled trial]
Abstract
Background: Mild cognitive impairment is a transitional stage between normal aging and dementia. It is important in terms of recognizing memory loss in older people as well as identifying a group of individuals at high risk of developing dementia and who may benefit from preventive strategies. Ginkgo biloba extract has been shown to possess polyvalent properties, such as anti-oxidation, anti-apoptosis and anti-inflammation. Ginkgo biloba extract appears to have a neuroprotective effect against neurodegenerative diseases.
Objective: To observe the efficacy of Ginkgo biloba leaf tablet in improving episodic memory of mild cognitive impairment.
Design, setting, participants and interventions: This is a multicenter, randomized, controlled trial. The authors enrolled generally healthy, ambulatory or ambulatory-aided amnestic subjects with MCI, 60 to 85 years old, who expressed a memory complaint from Huadong Hospital, seven Community Health Centers in Shanghai, and Shanghai First Welfare Institution. A total of 120 MCI patients were randomly assigned to the Ginkgo biloba leaf tablet group (treatment group, 60 cases) and control group (60 cases). The patients in the treatment group took Ginkgo biloba leaf tablets 3 times a day, 19.2 mg each dose. The control group did not receive any intelligence-promoting or vasodilator reflex treatment except some health care.
Main outcome measures: The patients were tested with nonsense picture recognition of the clinical memory scale and the logical memory test based on the Wechsler memory scale before and after treatment.
Results: After 6 months of treatment, the scores of the logical memory test and nonsense picture recognition were increased significantly in the treatment group (P<0.01, P<0.05), while the scores of the two tests from the control group had no statistically significant difference (P>0.05). After treatment, the positive rate of nonsense picture recognition was 55.17% in the treatment group, which was significantly higher than that of the control group at 32.73% (P<0.05). The efficacy rate of logical memory was 58.62% in the treatment group, also higher than 38.18% in the control group (P<0.05).
Conclusion: Ginkgo biloba leaf tablet showed good efficacy in promoting episodic memory function in MCI patients.
Similar articles
-
Strategies for the use of Ginkgo biloba extract, EGb 761® , in the treatment and management of mild cognitive impairment in Asia: Expert consensus.CNS Neurosci Ther. 2021 Feb;27(2):149-162. doi: 10.1111/cns.13536. Epub 2020 Dec 22. CNS Neurosci Ther. 2021. PMID: 33352000 Free PMC article.
-
A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings.Hum Psychopharmacol. 2002 Aug;17(6):267-77. doi: 10.1002/hup.412. Hum Psychopharmacol. 2002. PMID: 12404671 Clinical Trial.
-
[Effects of ginkgo biloba tablet in treating mild cognitive impairment].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Sep;32(9):1208-11. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012. PMID: 23185760 Clinical Trial. Chinese.
-
Effectiveness and Safety Profile of Ginkgo biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment.CNS Neurol Disord Drug Targets. 2021;20(4):378-384. doi: 10.2174/1871527320666210208125524. CNS Neurol Disord Drug Targets. 2021. PMID: 33557741 Clinical Trial.
-
EGb 761: ginkgo biloba extract, Ginkor.Drugs R D. 2003;4(3):188-93. doi: 10.2165/00126839-200304030-00009. Drugs R D. 2003. PMID: 12757407 Review.
Cited by
-
Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®.CNS Neurosci Ther. 2019 Feb;25(2):288-298. doi: 10.1111/cns.13095. CNS Neurosci Ther. 2019. PMID: 30648358 Free PMC article. Review.
-
Strategies for the use of Ginkgo biloba extract, EGb 761® , in the treatment and management of mild cognitive impairment in Asia: Expert consensus.CNS Neurosci Ther. 2021 Feb;27(2):149-162. doi: 10.1111/cns.13536. Epub 2020 Dec 22. CNS Neurosci Ther. 2021. PMID: 33352000 Free PMC article.
-
Treatment for mild cognitive impairment: systematic review.Br J Psychiatry. 2013 Sep;203(3):255-64. doi: 10.1192/bjp.bp.113.127811. Br J Psychiatry. 2013. PMID: 24085737 Free PMC article.
-
Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment.Front Neurol. 2025 Aug 15;16:1639924. doi: 10.3389/fneur.2025.1639924. eCollection 2025. Front Neurol. 2025. PMID: 40895100 Free PMC article.
-
Association Between Ginkgo Biloba Extract Prescriptions and Dementia Incidence in Outpatients with Mild Cognitive Impairment in Germany: A Retrospective Cohort Study.J Alzheimers Dis. 2022;86(2):703-709. doi: 10.3233/JAD-215348. J Alzheimers Dis. 2022. PMID: 35124648 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical